10,092 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Acquired by Select Equity Group L.P.

Select Equity Group L.P. bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,092 shares of the medical equipment provider's stock, valued at approximately $903,000.

Other hedge funds have also recently modified their holdings of the company. State of New Jersey Common Pension Fund D raised its position in Lantheus by 0.4% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock worth $2,364,000 after buying an additional 115 shares during the last quarter. Bleakley Financial Group LLC grew its stake in shares of Lantheus by 6.1% during the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock valued at $200,000 after acquiring an additional 129 shares during the period. Avantax Advisory Services Inc. grew its stake in shares of Lantheus by 5.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock valued at $213,000 after acquiring an additional 132 shares during the period. Foundry Partners LLC boosted its stake in Lantheus by 4.5% in the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after purchasing an additional 133 shares during the period. Finally, UMB Bank n.a. lifted its holdings in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after buying an additional 134 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Analysts Set New Price Targets

LNTH has been the subject of a number of research reports. B. Riley lowered their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Truist Financial decreased their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Finally, StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Lantheus currently has a consensus rating of "Buy" and an average price target of $132.67.

Insiders Place Their Bets

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. The trade was a 8.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. The trade was a 10.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock valued at $6,016,046 in the last three months. 1.50% of the stock is currently owned by insiders.

Lantheus Stock Down 1.8%

Shares of LNTH stock traded down $1.42 during trading hours on Tuesday, hitting $76.83. 1,208,591 shares of the company's stock were exchanged, compared to its average volume of 983,943. The firm has a market cap of $5.32 billion, a P/E ratio of 12.78 and a beta of 0.23. The firm has a 50 day moving average of $96.20 and a two-hundred day moving average of $92.76. Lantheus Holdings, Inc. has a fifty-two week low of $75.00 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. During the same quarter in the previous year, the business posted $1.69 EPS. The company's revenue for the quarter was up .8% on a year-over-year basis. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.